Your browser doesn't support javascript.
loading
Cost-Effectiveness of Erenumab for the Preventive Treatment of Migraine in Patients with Prior Treatment Failures in Sweden.
Mahon, Ronan; Lang, Andrea; Vo, Pamela; Huels, Jasper; Cooney, Philip; Danyliv, Andriy; Vudumula, Umakanth; Vadapalle, Sreelatha; Maniyar, Farooq; Goadsby, Peter J.
Afiliação
  • Mahon R; Value and Access, Novartis Ireland Limited, Dublin, Ireland. ronan.mahon@novartis.com.
  • Lang A; Market Access, Novartis Sverige AB, Kista, Sweden.
  • Vo P; Global Patient Access, Novartis Pharma AG, Basel, Switzerland.
  • Huels J; WW Market Access and HEOR, Novartis Pharma AG, Basel, Switzerland.
  • Cooney P; Value and Access, Novartis Ireland Limited, Dublin, Ireland.
  • Danyliv A; Value and Access, Novartis Ireland Limited, Dublin, Ireland.
  • Vudumula U; Value and Access, Novartis Healthcare Private Limited, Hyderabad, India.
  • Vadapalle S; Value and Access, Novartis Healthcare Private Limited, Hyderabad, India.
  • Maniyar F; Basildon and Thurrock University Hospitals and Queen Mary University, London, UK.
  • Goadsby PJ; NIHR-Wellcome Trust King's Clinical Research Facility, SLaM Biomedical Research Centre, King's College London, London, UK.
Pharmacoeconomics ; 39(3): 357-372, 2021 03.
Article em En | MEDLINE | ID: mdl-33491167
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transtornos de Enxaqueca Tipo de estudo: Clinical_trials / Health_economic_evaluation / Prognostic_studies Limite: Female / Humans País como assunto: Europa Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transtornos de Enxaqueca Tipo de estudo: Clinical_trials / Health_economic_evaluation / Prognostic_studies Limite: Female / Humans País como assunto: Europa Idioma: En Ano de publicação: 2021 Tipo de documento: Article